Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtrer
1.
Eur J Vasc Endovasc Surg ; 66(3): 397-406, 2023 09.
Article de Anglais | MEDLINE | ID: mdl-37356704

RÉSUMÉ

OBJECTIVE: Abdominal aortic graft and endograft infections (AGIs) are rare complications following aortic surgery. Radical surgery (RS) with resection of the infected graft and reconstruction with extra-anatomical bypass or in situ reconstruction is the preferred therapy. For patients unfit for RS, a semi-conservative (SC), graft preserving strategy is possible. This paper aimed to compare survival and infection outcomes between RS and SC treatment for AGI in a nationwide cohort. METHODS: Patients with abdominal AGI related surgery in Sweden between January 1995 and May 2017 were identified. The Management of Aortic Graft Infection Collaboration (MAGIC) criteria were used for the definition of AGI. Multivariable regression was performed to identify factors associated with mortality. RESULTS: One hundred and sixty-nine patients with surgically treated abdominal AGI were identified, comprising 43 SC (14 endografts; 53% with a graft enteric fistula [GEF] in total) and 126 RS (26 endografts; 50% with a GEF in total). The SC cohort was older and had a higher frequency of cardiac comorbidities. There was a non-significant trend towards lower Kaplan-Meier estimated five year survival for SC vs. RS (30.2% vs. 48.4%; p = .066). A non-significant trend was identified towards worse Kaplan-Meier estimated five year survival for SC patients with a GEF vs. without a GEF (21.7% vs. 40.1%; p = .097). There were significantly more recurrent graft infections comparing SC with RS (45.4% vs. 19.3%; p < .001). In a Cox regression model adjusting for confounders, there was no difference in five year survival comparing SC vs. RS (HR 1.0, 95% CI 0.6 - 1.5). CONCLUSION: In this national AGI cohort, there was no mortality difference comparing SC and RS for AGI when adjusting for comorbidities. Presence of GEF probably negatively impacts survival outcomes of SC patients. Rates of recurrent infection remain high for SC treated patients.


Sujet(s)
Anévrysme de l'aorte abdominale , Implantation de prothèses vasculaires , Procédures endovasculaires , Infections dues aux prothèses , Humains , Prothèse vasculaire/effets indésirables , Implantation de prothèses vasculaires/effets indésirables , Traitement conservateur/effets indésirables , Facteurs de risque , Études rétrospectives , Procédures endovasculaires/effets indésirables , Complications postopératoires/étiologie , Infections dues aux prothèses/chirurgie , Infections dues aux prothèses/étiologie , Résultat thérapeutique , Anévrysme de l'aorte abdominale/imagerie diagnostique , Anévrysme de l'aorte abdominale/chirurgie , Anévrysme de l'aorte abdominale/complications
2.
J Vasc Surg ; 76(2): 546-555.e3, 2022 08.
Article de Anglais | MEDLINE | ID: mdl-35470015

RÉSUMÉ

OBJECTIVE: The optimal revascularization modality following complete resection of aortic graft infection (AGI) without enteric involvement remains unclear. The purpose of this investigation is to determine the revascularization approach associated with the lowest morbidity and mortality using real-world data in patients undergoing complete excision of AGI. METHODS: A retrospective, multi-institutional study of AGI from 2002 to 2014 was performed using a standardized database. Baseline demographics, comorbidities, and perioperative variables were recorded. The primary outcome was infection-free survival. Descriptive statistics, Kaplan-Meier survival analysis, and univariate and multivariable analyses were performed. RESULTS: A total of 241 patients at 34 institutions from seven countries presented with AGI during the study period (median age, 68 years; 75% male). The initial aortic procedures that resulted in AGI were 172 surgical grafts (71%), 66 endografts (27%), and three unknown (2%). Of the patients, 172 (71%) underwent complete excision of infected aortic graft material followed by in situ (in-line) bypass (ISB), including antibiotic-treated prosthetic graft (35%), autogenous femoral vein (neo-aortoiliac surgery) (24%), and cryopreserved allograft (41%). Sixty-nine patients (29%) underwent extra-anatomic bypass (EAB). Overall median Kaplan-Meier estimated survival was 5.8 years. Perioperative mortality was 16%. When stratified by ISB vs EAB, there was a significant difference in Kaplan-Meier estimated infection-free survival (2910 days; interquartile range, 391-3771 days vs 180 days; interquartile range, 27-3750 days; P < .001). There were otherwise no significant differences in presentation, comorbidities, or perioperative variables. Multivariable Cox regression showed lower infection-free survival among patients with EAB (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.6-3.6; P < .001), polymicrobial infection (HR, 2.2; 95% CI, 1.4-3.5; P = .001), methicillin-resistant Staphylococcus aureus infection (HR, 1.7; 95% CI, 1.1-2.7; P = .02), as well as the protective effect of omental/muscle flap coverage (HR, 0.59; 95% CI, 0.37-0.92; P = .02). CONCLUSIONS: After complete resection of AGI, perioperative mortality is 16% and median overall survival is 5.8 years. EAB is associated with nearly a two and one-half-fold higher reinfection/mortality compared with ISB. Omental and/or muscle flap coverage of the repair appear protective.


Sujet(s)
Implantation de prothèses vasculaires , Co-infection , Staphylococcus aureus résistant à la méticilline , Infections dues aux prothèses , Sujet âgé , Prothèse vasculaire/effets indésirables , Co-infection/chirurgie , Femelle , Humains , Mâle , Infections dues aux prothèses/diagnostic , Infections dues aux prothèses/chirurgie , Réintervention , Études rétrospectives , Facteurs de risque , Résultat thérapeutique
3.
Eur J Vasc Endovasc Surg ; 62(6): 918-926, 2021 12.
Article de Anglais | MEDLINE | ID: mdl-34782231

RÉSUMÉ

OBJECTIVE: Abdominal aortic graft and endograft infection (AGI) is primarily treated by resection of the infected graft and restoration of distal perfusion through extra-anatomic bypass (EAB) or in situ reconstruction/repair (ISR). The aim of this study was to compare these surgical strategies in a nationwide multicentre retrospective cohort study. METHODS: The Swedish Vascular Registry (Swedvasc) was used to identify surgically treated abdominal AGIs in Sweden between January 1995 and May 2017. The primary aim was to compare short and long term survival, as well as complications for EAB and ISR. RESULTS: Some 126 radically surgically treated AGI patients were identified - 102 graft infections and 24 endograft infections - treated by EAB: 71 and ISR: 55 (23 neo-aorto-iliac systems, NAISs). No differences in early 30 day (EAB 81.7% vs. ISR 76.4%, p = .46), or long term five year survival (48.2% vs. 49.9%, p = .87) were identified. There was no survival difference comparing NAIS to other ISR strategies. The frequency of recurrent graft infection during follow up was similar: EAB 20.3% vs. ISR 17.0% (p = .56). Survival and re-infection rates of the new conduit did not differ between NAIS and other ISR strategies. Age ≥ 75 years (odds ratio [OR] 4.0, confidence interval [CI] 1.1 - 14.8), coronary artery disease (OR 4.2, CI 1.2 - 15.1) and post-operative circulatory complications (OR 5.2, CI 1.2 - 22.5) were associated with early death. Prolonged antimicrobial therapy (> 3 months) was associated with reduced long term mortality (HR 0.3, CI 0.1 - 0.9). CONCLUSION: In this nationwide multicentre study comparing outcomes of radically treated AGI, no differences in survival or re-infection rate could be identified comparing EAB and ISR.


Sujet(s)
Aorte abdominale/chirurgie , Implantation de prothèses vasculaires/effets indésirables , Prothèse vasculaire/effets indésirables , Procédures endovasculaires/effets indésirables , Infections dues aux prothèses/chirurgie , Sujet âgé , Aorte abdominale/imagerie diagnostique , Implantation de prothèses vasculaires/instrumentation , Implantation de prothèses vasculaires/mortalité , Procédures endovasculaires/instrumentation , Procédures endovasculaires/mortalité , Femelle , Humains , Mâle , Adulte d'âge moyen , Infections dues aux prothèses/imagerie diagnostique , Infections dues aux prothèses/microbiologie , Infections dues aux prothèses/mortalité , Enregistrements , Réintervention , Études rétrospectives , Appréciation des risques , Facteurs de risque , Suède , Facteurs temps , Résultat thérapeutique
4.
J Endovasc Ther ; 27(2): 328-333, 2020 04.
Article de Anglais | MEDLINE | ID: mdl-31989857

RÉSUMÉ

Purpose: To present a novel 4-branched endovascular aortic plug (BEVAP) for treatment of patients with infrarenal aortic graft infection. Case Reports: Two polymorbid male patients with aortic graft infections and an unsuturable diseased paravisceral aorta were treated under compassionate use with a custom-made stent-graft. The BEVAP is a factory-modified Zenith t-Branch thoracoabdominal endovascular graft with the distal tubular main graft portion removed, creating an aortic plug that excludes the abdominal aorta while maintaining perfusion to the visceral organs. The BEVAP device is deployed using a femoral approach, and the branches are accessed through an axillary approach. A standard axillobifemoral bypass is created to perfuse the lower body. One to 2 days later, the infected infrarenal graft is resected without the need of aortic clamping or closure of the aortic stump. The BEVAP device in these 2 cases resulted in thrombosis of the abdominal aorta and the infected graft prior to explantation. Conclusion: Using the BEVAP enables radical treatment of selected patients with hostile anatomy and infrarenal aortic graft infections who have an aneurysmal paravisceral aortic segment that prevents traditional radical surgical treatment with in situ reconstruction or extra-anatomical bypass.


Sujet(s)
Anévrysme de l'aorte abdominale/chirurgie , Prothèse vasculaire , Ablation de dispositif , Procédures endovasculaires/instrumentation , Infections dues aux prothèses/chirurgie , Endoprothèses , Sujet âgé , Antibactériens/administration et posologie , Antifongiques/administration et posologie , Prothèse vasculaire/effets indésirables , Implantation de prothèses vasculaires/effets indésirables , Implantation de prothèses vasculaires/instrumentation , Procédures endovasculaires/effets indésirables , Issue fatale , Humains , Mâle , Conception de prothèse , Infections dues aux prothèses/imagerie diagnostique , Infections dues aux prothèses/microbiologie , Endoprothèses/effets indésirables , Résultat thérapeutique
5.
Islets ; 9(3): e1296995, 2017 05 04.
Article de Anglais | MEDLINE | ID: mdl-28277987

RÉSUMÉ

Aims - Human pancreatic islets are known to die in response to the free fatty acid of sodium palmitate when cultured in vitro. This is in contrast to EndoC-ßH1 cells, which in our hands are not sensitive to the cell death-inducing effects sodium palmitate, making these cells seemingly unsuitable for lipotoxicity studies. However, the EndoC-ßH1 cells are routinely cultured in a nutrient mixture based on Dulbecco's Modified Eagle Medium (DMEM), which may not be the optimal choice for studies dealing with lipotoxicity. The aim of the present investigation was to define culture conditions that render EndoC-ßH1 cells sensitive to toxic effects of sodium palmitate. Methods - EndoC-ßH1 cells were cultured at standard conditions in either DMEM or DMEM/F12 culture medium. Cell death was analyzed using propidium iodide staining and flow cytometry. Insulin release and content was quantified using a human insulin ELISA. Results - We presently observe that substitution of DMEM for a DMEM/Ham's F12 mixture (50%/50% vol/vol) renders the cells sensitive to the apoptotic effects of sodium palmitate and sodium palmitate + high glucose leading to an increased cell death. Supplementation of the DMEM culture medium with linoleic acid partially mimicked the effect of DMEM/F12. Culture of EndoC-ßH1 cells in DMEM/F12 resulted also in increased proliferation, ROS production and insulin contents, but markers for metabolic stress, autophagy or amyloid deposits were unaffected. Conclusions - The culture conditions for EndoC-ßH1 cells can be modified so these cells display signs of lipotoxicity in response to sodium palmitate.


Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Milieux de culture/pharmacologie , Antienzymes/pharmacologie , Cellules à insuline/effets des médicaments et des substances chimiques , Acide palmitique/pharmacologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Milieux de culture/composition chimique , Glucose/pharmacologie , Humains , Insuline/métabolisme , Cellules à insuline/métabolisme , Acide linoléique/pharmacologie , Espèces réactives de l'oxygène/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE